Literature DB >> 27965286

Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank.

Worta McCaskill-Stevens1, Deborah C Pearson2, Barnett S Kramer2, Leslie G Ford2, Scott M Lippman3.   

Abstract

In late 2015, the NCI Division of Cancer Prevention convened cancer prevention research experts and stakeholders to discuss the current state of cancer prevention research, identify key prevention research priorities for the NCI, and identify studies that could be conducted within the NCI Community Oncology Research Program. Goals included identifying cancer prevention research opportunities offering the highest return on investment, exploring the concept of precision prevention and what is needed to advance this area of research, and identifying possible targets for prevention. Four study populations were considered for cancer prevention research: healthy people, those at increased risk for a specific cancer, people with preneoplastic lesions, and children, adolescents, and young adults. Priorities that emerged include screening (e.g., surveillance intervals, tomosynthesis vs. digital mammography), a pre-cancer genome atlas (PreTCGA), HPV vaccines, immunoprevention of noninfectious origins, and overdiagnosis. Challenges exist, as the priority list is ambitious and potentially expensive. Clinical trials need to be carefully designed to include and maximize prospective tissue collection. Exploring existing cofunding mechanisms will likely be necessary. Finally, relationships with a new generation of physician specialists will need to be cultivated to reach the target populations. Cancer Prev Res; 10(2); 99-107. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27965286      PMCID: PMC5292088          DOI: 10.1158/1940-6207.CAPR-16-0230

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  28 in total

1.  Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

Authors:  S von Mensdorff-Pouilly; A A Verstraeten; P Kenemans; F G Snijdewint; A Kok; G J Van Kamp; M A Paul; P J Van Diest; S Meijer; J Hilgers
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 2.  Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance.

Authors:  Bridget Keenan; Elizabeth M Jaffee
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.

Authors:  Andrew C Chen; Andrew J Martin; Bonita Choy; Pablo Fernández-Peñas; Robyn A Dalziell; Catriona A McKenzie; Richard A Scolyer; Haryana M Dhillon; Janette L Vardy; Anne Kricker; Gayathri St George; Niranthari Chinniah; Gary M Halliday; Diona L Damian
Journal:  N Engl J Med       Date:  2015-10-22       Impact factor: 91.245

5.  15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Authors:  Min Yan; Ronald M Rerko; Petra Platzer; Dawn Dawson; Joseph Willis; Min Tong; Earl Lawrence; James Lutterbaugh; Shilong Lu; James K V Willson; Guangbin Luo; Jack Hensold; Hsin-Hsiung Tai; Keith Wilson; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

Review 6.  Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer.

Authors:  Carolyn E Clark; Gregory L Beatty; Robert H Vonderheide
Journal:  Cancer Lett       Date:  2008-11-14       Impact factor: 8.679

7.  Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.

Authors:  William N William; Vassiliki Papadimitrakopoulou; J Jack Lee; Li Mao; Ezra E W Cohen; Heather Y Lin; Ann M Gillenwater; Jack W Martin; Mark W Lingen; Jay O Boyle; Dong M Shin; Nadarajah Vigneswaran; Nancy Shinn; John V Heymach; Ignacio I Wistuba; Ximing Tang; Edward S Kim; Pierre Saintigny; Elizabeth A Blair; Timothy Meiller; J Silvio Gutkind; Jeffrey Myers; Adel El-Naggar; Scott M Lippman
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

8.  15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.

Authors:  Michael G Backlund; Jason R Mann; Vijaykumar R Holla; F Gregory Buchanan; Hsin-Hsiung Tai; Erik S Musiek; Ginger L Milne; Sharada Katkuri; Raymond N DuBois
Journal:  J Biol Chem       Date:  2004-11-12       Impact factor: 5.157

9.  Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota.

Authors:  Kristoffer Forslund; Falk Hildebrand; Trine Nielsen; Gwen Falony; Emmanuelle Le Chatelier; Shinichi Sunagawa; Edi Prifti; Sara Vieira-Silva; Valborg Gudmundsdottir; Helle K Pedersen; Manimozhiyan Arumugam; Karsten Kristiansen; Anita Yvonne Voigt; Henrik Vestergaard; Rajna Hercog; Paul Igor Costea; Jens Roat Kultima; Junhua Li; Torben Jørgensen; Florence Levenez; Joël Dore; H Bjørn Nielsen; Søren Brunak; Jeroen Raes; Torben Hansen; Jun Wang; S Dusko Ehrlich; Peer Bork; Oluf Pedersen
Journal:  Nature       Date:  2015-12-02       Impact factor: 49.962

10.  Epidermal EGFR controls cutaneous host defense and prevents inflammation.

Authors:  Beate M Lichtenberger; Peter A Gerber; Martin Holcmann; Bettina A Buhren; Nicole Amberg; Viktoria Smolle; Holger Schrumpf; Edwin Boelke; Parinaz Ansari; Colin Mackenzie; Andreas Wollenberg; Andreas Kislat; Jens W Fischer; Katharina Röck; Jürgen Harder; Jens M Schröder; Bernhard Homey; Maria Sibilia
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956

View more
  5 in total

1.  Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.

Authors:  Smruthy Sivakumar; F Anthony San Lucas; Tina L McDowell; Wenhua Lang; Li Xu; Junya Fujimoto; Jianjun Zhang; P Andrew Futreal; Junya Fukuoka; Yasushi Yatabe; Steven M Dubinett; Avrum E Spira; Jerry Fowler; Ernest T Hawk; Ignacio I Wistuba; Paul Scheet; Humam Kadara
Journal:  Cancer Res       Date:  2017-09-26       Impact factor: 12.701

Review 2.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

3.  Patient and Provider Web-Based Decision Support for Breast Cancer Chemoprevention: A Randomized Controlled Trial.

Authors:  Katherine D Crew; Gauri Bhatkhande; Thomas Silverman; Jacquelyn Amenta; Tarsha Jones; Julia E McGuinness; Jennie Mata; Ashlee Guzman; Ting He; Jill Dimond; Wei-Yann Tsai; Rita Kukafka
Journal:  Cancer Prev Res (Phila)       Date:  2022-10-04

Review 4.  Smoking and Lung Cancer: A Geo-Regional Perspective.

Authors:  Zahraa Rahal; Shaza El Nemr; Ansam Sinjab; Hassan Chami; Arafat Tfayli; Humam Kadara
Journal:  Front Oncol       Date:  2017-09-01       Impact factor: 6.244

Review 5.  Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.

Authors:  Sara Saab; Hussein Zalzale; Zahraa Rahal; Yara Khalifeh; Ansam Sinjab; Humam Kadara
Journal:  Front Immunol       Date:  2020-02-11       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.